William M. Greenman

President and Chief Executive Officer at CERUS

Board

Since April 2011

Age

57 years

Education

Holds a B.A.S. in economics and biological sciences from Stanford University.

Tenure

Joined Cerus Corporation in 1995 and progressed through roles including Director of Business Development, Vice President of Business Development, President of Cerus Europe, Senior Vice President of Business Development and Marketing, Chief Business Officer, and became President and Chief Executive Officer in April 2011.

Also at CERUS

CMM

Carol M. Moore

SVP, Regulatory Affairs and Quality

Chrystal Jensen

Chief Legal Officer and General Counsel

KDG

Kevin D. Green

Chief Financial Officer

About

William M. Greenman is currently 57 years old as of April 2024, reflecting decades of professional growth and dedication in the biotechnology sector. He boasts a strong educational background, holding a B.A.S. in economics and biological sciences from Stanford University, which has laid the foundation for his leadership and strategic vision.

His career at Cerus Corporation began in 1995 when he joined as Director of Business Development. Over the years, he has advanced through key roles including Vice President of Business Development, President of Cerus Europe, Senior Vice President of Business Development and Marketing, and Chief Business Officer. His significant promotion to President and Chief Executive Officer came in April 2011, marking a milestone in his longstanding tenure with the company.

Before his remarkable journey at Cerus, he gained valuable industry experience in various marketing and business development roles at Baxter’s Biotech Division and also had a brief stint in venture capital. His broad experience in both executive leadership and board roles, including his involvement with Aduro Biotech, Inc. and Chinook Therapeutics, further underscores his comprehensive expertise in the healthcare and biotechnology sectors.

$CERS Performance Under William M. Greenman

Past Roles

Organization	Role	Date Range	Details
Chinook Therapeutics	Board of Directors	N/A - August 2023	Tenure ended after the company's acquisition by Novartis AG
Cerus Corporation	Senior Vice President, Business Development and Marketing	August 2008 - April 2011	Held prior to becoming CEO
Cerus Corporation	Chief Business Officer	April 2010	Held concurrently with other roles
Cerus Corporation	President, Cerus Europe	2006 - August 2008	Focused on European operations
Cerus Corporation	Vice President, Business Development	1999 - 2006	Early leadership role in business development
Cerus Corporation	Director of Business Development	1995 - 1999	Initial role at Cerus
Baxter's Biotech Division	Marketing and Business Development positions	1991 - 1995	Various roles prior to joining Cerus

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$763,750	Annual	Fixed annual salary paid for the role as President and Chief Executive Officer
All Other Compensation	$2,372	Annual	Comprises Group-term life insurance premiums: $2,322 and Cell phone accessory stipend: $50

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation

Metric	Value	Details
Target Bonus	$539,000	70% of base salary
Achievement Rate	50%	Final performance rate determined by the Compensation Committee
Actual Bonus Payout	$269,500	50% of target bonus
Performance Weights	Quantitative: 50%, Qualitative: 45%, Strategic: 5%	Bonus plan is based on a mix of quantitative, qualitative, and strategic goals

Performance-Based RSU (PRSU) Awards

Metric	Value	Details
Performance Metrics	Revenue & Clinical Trial Enrollment	Specific revenue and clinical trial enrollment goals are confidential
Threshold	173,250 shares	Minimum performance requirement
Target	192,500 shares	Target performance level
Maximum	211,750 shares	Maximum cap on award units
Vesting Conditions	Performance-based	Vesting occurs upon achievement of the performance conditions and continued service over the performance period
Performance Period	Mar 1, 2023 – Dec 31, 2025	Three-year evaluation period
Grant Date	April 3, 2023	The date on which the PRSU awards were granted
Grant Date Fair Value	$550,550 each	Fair value per PRSU award for Revenue and Clinical Trial categories (Total $1,101,100 for both)
Grant Date Stock Price	N/A	Specific stock price on the grant date was not provided